Analysis of over 16,000 patients switched to HADLIMA® from HUMIRA® (adalimumab) showed a 1.3% switchback rate over a 12-month follow-up period1
Data demonstrated the switching cohort had an average first-year
New pooled post-hoc analysis of Phase 3 data evaluates consistency of VTAMA cream efficacy across diverse atopic dermatitis patient subgroups
Organon (NYSE:OGN), a global healthcare company with a mission to deliver
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend
Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE:OGN) He joins Entera with two decades of clinical development, regulatory execution, and
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly
No new safety signals identified during additional three years of extended use
Organon holds exclusive global licensing rights to MIUDELLA
Organon (NYSE:OGN), a global healthcare company with a mission to
New data will represent one of the first large-scale real-world effectiveness analyses of VTAMA cream in patients with atopic dermatitis (AD)
Organon (NYSE:OGN), a global healthcare company with a mission to deliver
KIRKLAND, QC, Sept. 28, 2026 /CNW/ -- Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic
Sebela’s sNDA Seeks to Extend Approved Duration of Use from 3 to 6 Years
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women’s Health Collective Canada (WHCC) and the Partnership for Women’s Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant
Healthcare Providers, Healthcare Settings, and Participating Pharmacies Can Now Begin Required Training and Certification in Preparation for MIUDELLA’s Launch Later This Year
Organon (NYSE:OGN), a global healthcare
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend
The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic
25-year industry leader to drive continued growth and expand access to medicines in CanadaKIRKLAND, QC, July 22, 2026 /CNW/ -- Organon Canada, a global healthcare company dedicated to improving the health of women, is
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly
